{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-035667","form_type":"8-K","ticker":"QCLS","cik":"0001321834","company_name":"Q/C TECHNOLOGIES, INC.","filed_at":"2023-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.600472+00:00","generated_at":"2026-06-10T04:36:15.490971+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MyMD reports updated Phase 2 data for MYMD-1 in sarcopenia; TNF-α reduction statistically significant at 1050mg","bullets":["Cohort 4 (1050mg) showed reduction in TNF-α over 28 days vs placebo (p=0.002 to 0.008).","Phase 2 study met all primary PK and secondary safety/tolerability endpoints across multiple doses.","FDA accepted IND for MYMD-1 in rheumatoid arthritis; Phase 2 trials planned.","Company plans to present clinical safety report to FDA and seek guidance for Phase 3 trial in sarcopenia."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-035667","json":"https://secwatch.observer/filing/0001493152-23-035667.json","markdown":"https://secwatch.observer/filing/0001493152-23-035667.md","text":"https://secwatch.observer/filing/0001493152-23-035667.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321834/000149315223035667/0001493152-23-035667-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321834/000149315223035667/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T04:36:15.490971+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}